Healius Limited posted a modest revenue increase and underlying loss improvement for FY26, overshadowed by a substantial non-cash goodwill impairment and ongoing sector pressures.
- Revenue grew 2.2% to $1.373 billion
- Underlying loss after tax narrowed 47% to $13.2 million
- Reported loss widened to $415.6 million due to $332 million goodwill impairment
- Pathology segment revenue up 1.8% with margin gains in second half
- Agilex Biolabs revenue and earnings surged; sale process underway
Financial Results Marked by Large Impairment Charge
Healius Limited (ASX:HLS) revealed a mixed picture in its FY26 results, with revenue nudging up 2.2% to $1.373 billion and underlying loss after tax improving by nearly half to $13.2 million. However, these encouraging operational signs were eclipsed by a $332 million non-cash goodwill impairment, driving the reported loss after tax to a substantial $415.6 million, more than double the prior year’s $151.2 million loss.
The impairment reflects lower near-term cash flow expectations and a higher weighted average cost of capital, leaving the carrying value of goodwill at $98 million, down sharply from $430 million a year earlier. The company cautions that any further negative shifts in assumptions could trigger additional impairments.
Pathology Segment Shows Resilience Amid Sector Headwinds
Healius’ core pathology business posted a 1.8% revenue increase to $1.33 billion despite a 1.3% volume decline, supported by favourable pricing and revenue mix. The second half of FY26 saw margin improvement, with EBITDA rising 6.4% to $247.9 million and EBIT climbing 65% to $23.8 million for the full year. The EBIT margin lifted to 2.8% in 2H26 from 1.8% for the full year.
Cost containment played a key role, with labour expenses flat year-on-year despite inflation and Fair Work Commission wage rulings. A 5% reduction in full-time equivalent staff and digital automation initiatives, including AI for workforce planning and invoicing, contributed to a 2.9% labour cost reduction in the second half. Consumable costs also fell 3.8% through procurement efficiencies and test mix optimisation.
Volume pressures stemmed from Medicare funding changes, including tightened criteria for Vitamin B12 and urine testing, and a 0.9% decline in GP attendances. The network footprint was rationalised, with 100 fewer collection centres by year end. Growth in genomic diagnostics, public hospital contracts, veterinary pathology, and clinical trials helped offset these challenges.
Digital Transformation and AI Integration Accelerate
Healius completed the major phase of its digital transformation, transitioning digital costs into underlying results from January 2026. The Medway Collections Portal now processes over 80% of episodes digitally across 1,700+ centres, while online booking and patient apps enhance access. Referrers benefit from integrated eReferrals and AI-enabled workflows that reduce manual data entry and errors.
Laboratory operations are being modernised with national Instrument Manager and Pathway Laboratory Portal rollouts, enabling shared staffing, specialised testing, and improved reporting. AI applications like IBEX support complex histopathology decision-making, improving turnaround times. The company plans to expand AI to back-office functions in FY27.
Agilex Biolabs Delivers Strong Growth; Sale Process Underway
Agilex Biolabs, Healius’ bioanalytical division, posted a 14.1% revenue increase to $43.6 million and a 67.2% jump in underlying EBITDA to $10.7 million. EBIT more than doubled to $6.4 million, driven by a strategic pivot to large molecule development and the opening of a new Brisbane lab in August 2025.
Following multiple unsolicited offers, Healius is actively pursuing a sale of Agilex Biolabs, with due diligence underway. UBS Securities Australia Limited is advising on the process, with updates expected ahead of the Annual General Meeting.
Balance Sheet and Capital Management
Net debt rose to $32.8 million from a net cash position of $57.2 million in FY25, primarily due to growth capital expenditure, a historical ATO dispute settlement, divestment costs related to Lumus Imaging, and restructuring charges. Despite this, Healius remains comfortably within banking covenants, with a gearing ratio of 1.2x and interest cover of 8.8x.
Cash flow from operations declined to $211.1 million, with free cash flow negative $34.8 million, reflecting ongoing investment and non-recurring costs. The company emphasises restoring sustainable positive cash flow through revenue growth and cost discipline in FY27.
Sector Challenges and Strategic Focus
Healius continues to navigate a challenging pathology sector environment marked by flat or declining Medicare indexation, volume headwinds from GP attendance shifts, and wage inflation following Fair Work Commission rulings on gender-based undervaluation. The full-year wage impact for pathology collectors and laboratory staff is expected to increase by approximately $15 million in FY27.
The company is engaging with the Department of Health and Australian Pathology on potential Medicare Benefits Schedule adjustments to offset rising labour costs that cannot be passed directly to patients. Meanwhile, Healius is doubling down on digital technologies, network optimisation, and emerging diagnostic areas like genomics and veterinary pathology to drive growth and margin improvement.
Healius’ commitment to climate strategy and sustainability is integrated into its broader operational and financial plans, aiming to reduce costs through energy efficiency and enhance resilience against climate-related risks.
Bottom Line?
Healius faces a pivotal year balancing digital transformation gains and cost pressures with the outcome of Agilex Biolabs’ sale and Medicare funding uncertainties.
Questions in the middle?
- How will ongoing Medicare funding constraints affect Healius’ volume and pricing strategies?
- What impact will the Agilex Biolabs sale have on Healius’ capital structure and strategic focus?
- Can digital transformation and AI investments deliver sustainable margin improvements amid rising labour costs?